UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Holdings in Catalent, Inc. (NYSE:CTLT)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Catalent, Inc. (NYSE:CTLT) by 4.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,024,240 shares of the company’s stock after acquiring an additional 45,564 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Catalent were worth $62,038,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Catalent by 12.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 37,982 shares of the company’s stock valued at $2,301,000 after purchasing an additional 4,088 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in shares of Catalent by 166.5% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,382,424 shares of the company’s stock worth $83,733,000 after buying an additional 863,624 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of Catalent by 9.3% in the third quarter. BNP Paribas Financial Markets now owns 267,219 shares of the company’s stock valued at $16,185,000 after buying an additional 22,785 shares during the last quarter. Brooklyn Investment Group purchased a new position in shares of Catalent in the third quarter worth about $31,000. Finally, Quantbot Technologies LP acquired a new position in Catalent during the third quarter worth about $7,222,000.

Catalent Stock Up 0.6 %

Shares of NYSE:CTLT opened at $61.45 on Tuesday. The business has a 50-day moving average price of $59.93 and a 200 day moving average price of $58.55. The company has a market capitalization of $11.15 billion, a price-to-earnings ratio of -27.19, a PEG ratio of 2.43 and a beta of 1.16. Catalent, Inc. has a 12-month low of $36.74 and a 12-month high of $61.50. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.18). The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. Catalent’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.10) EPS. Sell-side analysts expect that Catalent, Inc. will post 0.84 EPS for the current year.

Wall Street Analyst Weigh In

CTLT has been the topic of a number of research reports. Robert W. Baird reissued a “neutral” rating and issued a $63.50 target price on shares of Catalent in a research note on Tuesday, September 24th. William Blair reissued a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Baird R W cut Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Finally, StockNews.com upgraded Catalent from a “sell” rating to a “hold” rating in a report on Monday. Eight analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Catalent has an average rating of “Hold” and a consensus price target of $63.40.

Insider Buying and Selling

In related news, insider David Mcerlane sold 1,994 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the sale, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. The trade was a 5.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the transaction, the director now owns 10,835 shares in the company, valued at $646,849.50. This represents a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 5,114 shares of company stock worth $305,931. Company insiders own 0.31% of the company’s stock.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.